BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 23470460)

  • 1. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
    Avgeris M; Stravodimos K; Scorilas A
    Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
    Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
    Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG gene expression and its possible significance in prostate cancers.
    Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
    Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.
    Rose A; Xu Y; Chen Z; Fan Z; Stamey TA; McNeal JE; Caldwell M; Peehl DM
    Cancer Lett; 2005 Sep; 227(2):213-22. PubMed ID: 16112424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
    Nikoleishvili D; Pertia A; Tsintsadze O; Gogokhia N; Chkhotua A
    Georgian Med News; 2007 Feb; (143):34-8. PubMed ID: 17404436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
    Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL
    Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
    Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
    Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
    Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
    J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.
    Tiniakos DG; Mitropoulos D; Kyroudi-Voulgari A; Soura K; Kittas C
    Urology; 2006 Jan; 67(1):204-8. PubMed ID: 16413376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
    Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
    Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differentially expressed genes in prostate cancer and benign prostatic hyperplasia].
    Zhang T; Xu Y; Tang H; Liu M; Ren D; Niu Y
    Zhonghua Nan Ke Xue; 2004 Dec; 10(12):897-9. PubMed ID: 15638016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.